Mr. Fletcher Payne report

APTOSE BIOSCIENCES ANNOUNCES RESULTS OF RECONVENED ANNUAL AND SPECIAL SHAREHOLDERS MEETING AND APPOINTMENT OF ERNST & YOUNG LLP AS NEW AUDITOR

Aptose Biosciences Inc. has released results of its reconvened annual and special meeting of shareholders held on Aug. 22, 2025.

At the meeting, shareholders voted in favor of the appointment of Ernst & Young LLP (EY) as the company's independent registered public accounting firm.

"We are pleased to welcome Ernst & Young as our new auditor," said Fletcher Payne, ssenior vice-president and chief financial officer and chief business officer of Aptose. "Their global expertise and deep experience in the life sciences sector will support our continued growth and commitment to transparency."

EY is a Big Four global accounting firm that offers a complete spectrum of tax, assurance, and advisory services; they have been selected due to their expertise, capabilities, fit and understanding of the company's industry and business.

The company also announced that it has received an additional advance of $1.5-million (U.S.) in financing from Hanmi Pharmaceutical Co. Ltd. as part of a $8.5-million (U.S.) loan facility agreement with Hanmi announced on June 20, 2025. To date, Aptose has received an aggregate of $7.1-million (U.S.) under the loan agreement, to support continued clinical development of tuspetinib.

About Aptose Biosciences Inc.

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS), has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML.

We seek Safe Harbor.